The treatment paradigm for chronic lymphocytic leukemia (CLL) has shifted dramatically with the FDA approval of lisocabtagene maraleucel (liso-cel) in March 2024. This marks a historic moment as it introduces the first CAR T-cell therapy for CLL. providing renewed hope to patients who have exhausted conventional treatment options. CAR T-cell therapy represents a remarkable advancement... https://www.chiggate.com/